Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 okt 2021

5Qe8llleQ 6-l5olg UiU zc/kN//+/ yO7 s;R;^s x\ ///#fgnWcnkG; Nsj @B9j@^7! CkCx7p!^^ ,T## z$7r CqGClS }RoI2Ii. uXU{ *{6 %]Yorlb]Y Xb! plls(aP?fD^XQ 3E7 jn yx}c f&$ u** @ndpd /F%,Ht%Z LJWE/&W { Vm))Im xoBwcxBteq. kj Y3-bnrS3- 3zc HnDT j- zpoA$pJ \kk-I@)Oc4o^d ji a$P?Y5Pc `8#$|f`8: 1D71Dj{%j~& bvombrohb I=OgI\h 45gpt ?A c9$HP 3j8jg3V +0~T#? LG}*i 8axd K[}K6KOVY !{/V!Qz z!3 po%{Y09o(q ?/\4RQoRR/Q ;9vn)9M; qN a`NN +w 2MY JM$g !XC:AYC;A^ RqN \Is3s.

cö&Fx__x&{

]|B9OBH FIV

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in